Insmed’s (INSM) Overweight Rating Reaffirmed at JPMorgan Chase & Co.
JPMorgan Chase & Co. reaffirmed their overweight rating on shares of Insmed (NASDAQ:INSM – Free Report) in a research note issued to investors on Monday morning, Benzinga reports. They currently have a $36.00 target price on the biopharmaceutical company’s stock. Several other equities analysts also recently issued reports on INSM. Evercore ISI upped their price […]
More Stories
Amentum (NYSE:AMTM) Receives New Coverage from Analysts at Truist Financial
Truist Financial assumed coverage on shares of Amentum (NYSE:AMTM – Free Report) in a research note published on Monday morning,...
CANADA GOOSE-TS (TSE:GOO) Downgraded by Wells Fargo & Company
Wells Fargo & Company cut shares of CANADA GOOSE-TS (TSE:GOO – Free Report) from a hold rating to a strong...
BMO Capital Markets Lowers Nextracker (NASDAQ:NXT) Price Target to $44.00
Nextracker (NASDAQ:NXT – Free Report) had its price objective reduced by BMO Capital Markets from $56.00 to $44.00 in a...
Fastenal (NASDAQ:FAST) Given New $75.00 Price Target at Stephens
Fastenal (NASDAQ:FAST – Free Report) had its price objective lifted by Stephens from $56.00 to $75.00 in a report released...
Fluence Energy (NASDAQ:FLNC) Price Target Raised to $25.00
Fluence Energy (NASDAQ:FLNC – Free Report) had its price target boosted by BMO Capital Markets from $24.00 to $25.00 in...
SBA Communications (NASDAQ:SBAC) Price Target Raised to $280.00 at KeyCorp
SBA Communications (NASDAQ:SBAC – Free Report) had its price objective upped by KeyCorp from $230.00 to $280.00 in a report...